ArkBio Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $15M
Latest Deal Amount
  • Investors
  • 5

ArkBio General Information

Description

Developer of innovative therapeutics created to address unmet medical needs in the area of respiratory viral infection and viral hepatitis. The company's leading drug AK0529 specifically inhibits RSV (Respiratory Syncytial Virus) replication by blocking viral entry and syncytial formation, providing an effective first-line antiviral therapy for RSV infection in infants and the elderly.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • Room 701, 780 Cailun Road
  • Pudong New Area
  • Shanghai, 201203
  • China
+86 021 0000 0000

ArkBio Timeline

2017201820192020
Financing Round
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ArkBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series C) 01-Jun-2018 $15M 000.00 Completed Generating Revenue
3. Early Stage VC (Series A1) 06-Feb-2017 000 000.00 0000 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series A) 08-Apr-2015 $3.5M $3.5M 0000 Completed Clinical Trials - Phase 1
1. Early Stage VC Completed Clinical Trials - Phase 1
To view ArkBio’s complete valuation and funding history, request access »

ArkBio Executive Team (4)

Name Title Board Seat Contact Info
Zheng Wu Ph.D Chief Executive Officer & Founder
Haiqing Yuan Ph.D Chief Scientific Officer
Stephen Toovey Ph.D Chief Medical Officer
Gianni Gromo Ph.D Scientific Advisor
To view ArkBio’s complete executive team members history, request access »

ArkBio Board Members (1)

Name Representing Role Since
Xubo Hu Qiming Venture Partners Board Member 000 0000
To view ArkBio’s complete board members history, request access »

ArkBio Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Oriza Ventures Venture Capital Minority 000 0000 000000 0
YuanBio Venture Capital Venture Capital Minority 000 0000 000000 0
Morningside Group Venture Capital Minority 000 0000 000000 0
Qiming Venture Partners Venture Capital Minority 000 0000 000000 0
TF Capital Venture Capital Minority 000 0000 000000 0
To view ArkBio’s complete investors history, request access »